Back to Journals » Clinical Ophthalmology » Volume 7

Treatment of visual problems after intracorneal ring implantation

Authors Yildirim A, Uslu H, Kara N, Ozgurhan EB

Received 26 March 2013

Accepted for publication 26 April 2013

Published 24 June 2013 Volume 2013:7 Pages 1251—1255

DOI https://doi.org/10.2147/OPTH.S45773

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4



Aydin Yildirim,1 Hasim Uslu,1 Necip Kara,2 Engin Bilge Ozgurhan2

1Fatih University, Department of Ophthalmology, Sema Research and Treatment Hospital, Istanbul, Turkey; 2Beyoglu Eye Research and Training Hospital, Istanbul, Turkey

Purpose: To report the effect of wavefront-guided photorefractive keratectomy and corneal collagen cross-linking (CXL) on visual problems after Ferrara ring segment placement.
Materials and methods: A 32-year-old male patient was treated with a Ferrara ring segment for keratoconus. One year later, the ring was removed due to severe glare complaints. After 6 months, wavefront-guided photorefractive keratectomy and CXL were applied simultaneously to correct high order aberration and refractive error.
Results: Six months after the wavefront-guided photorefractive keratectomy and CXL, the uncorrected distance visual acuity was 20/25, and there was a 30% decrease in coma aberrations. The glare complaint regressed.
Conclusion: Wavefront-guided surface ablation and CXL may reduce high order aberrations and glare complaints after intrastromal corneal ring implantation.

Keywords: keratoconus, Ferrara ring, corneal collagen cross-linking, corneal wavefront, photorefractive keratectomy

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.